Stock Watch: Gaming The US Health Care System
Pharmacies Should Be Held To Account For Role In Drug Price Inflation
Executive Summary
The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.
You may also be interested in...
Stock Watch: Biogen, Blood In The Water
When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.
Pharma’s 340B Dispute Resolution Arguments May Get Boost From Supreme Court’s Patent Ruling
As stakeholders begin to mull the impact of the Arthrex opinion, HHS withdraws its advisory opinion concluding manufacturers are legally bound to provide 340B discounts to contract pharmacies, and Lilly takes aim at 340b contract pharmacy ‘replenishment’ model.
Valeant Reset: Will It Cure What Ails It?
Valeant Pharmaceuticals International Inc. finally filed its 10-K with the Securities and Exchange Commission, disclosing new investigations into the firm's pricing and business practices and further details about its shady dealings with the specialty pharmacy Philidor Rx Services Inc. The company also revealed its plans to shake up its board – nominating three new members.